| Literature DB >> 24958267 |
Antje Hutschenreuther1, Gerd Birkenmeier2, Marina Bigl3, Knut Krohn4, Claudia Birkemeyer5.
Abstract
In cancer research, cell lines are used to explore the molecular basis of the disease as a substitute to tissue biopsies. Breast cancer in particular is a very heterogeneous type of cancer, and different subgroups of cell lines have been established according to their genomic profiles and tumor characteristics. We applied GCMS metabolite profiling to five selected breast cancer cell lines and found this heterogeneity reflected on the metabolite level as well. Metabolite profiles of MCF-7 cells belonging to the luminal gene cluster proved to be more different from those of the basal A cell line JIMT-1 and the basal B cell lines MDA-MB-231, MDA-MB-435, and MDA-MB-436 with only slight differences in the intracellular metabolite pattern. Lactate release into the cultivation medium as an indicator of glycolytic activity was correlated to the metabolite profiles and physiological characteristics of each cell line. In conclusion, pantothenic acid, beta-alanine and glycerophosphoglycerol appeared to be related to the glycolytic activity designated through high lactate release. Other physiological parameters coinciding with glycolytic activity were high glyoxalase 1 (Glo1) and lactate dehydrogenase (LDH) enzyme activity as well as cell migration as an additional important characteristic contributing to the aggressiveness of tumor cells. Metabolite profiles of the cell lines are comparatively discussed with respect to known biomarkers of cancer progression.Entities:
Year: 2013 PMID: 24958267 PMCID: PMC3937838 DOI: 10.3390/metabo3041084
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Characterization of breast cancer cell lines for their histological characteristics, cancer specific gene expressions, and tumor aggressiveness.
| Parameter | MCF-7 | MDA-MB-231 | MDA-MB-435 | MDA-MB-436 | JIMT-1 | Reference |
|---|---|---|---|---|---|---|
| Origin | PE | PE | PE | PE | PE | [ |
| Tumor type | IDC | AC | IDC | IDC | AC | [ |
| Differentiation grade | High | Poor | Poor | Poor | Poor | [ |
| ER, PR, ERB/B2 status | ER+/PR+ | TN | TN | TN | ERB/B2+ | [ |
| p53 status | wt | m | m | m | m | [ |
| +/ | +++/ | +++/ | ++/ | n.a. | [ | |
| Tumors in nude mice | P | LI | LI | LI | Yes, not further specified | [ |
| Gene cluster | luminal | basal B | basal B | basal B | basal A/ ERB/B2 | [ |
PE = pleural effusion; IDC = Invasive ductal carcinoma; AC = adeno carcinoma; ER = estrogen receptor; PR = progesterone receptor; TN = triple negative; wt = wild type; m = mutated; P = primary tumor; no local invasiveness or metastasis; LI = local invasiveness.
Figure 1Principal component analysis (PCA) of metabolite profiles from the five breast cancer cell lines. MCF-7 is clearly separated from the other cell lines. PC 1 includes 81% of variability, PC 2 7.5%. n = 6 for each cell line, only metabolites with significant differences between at least two cell lines (p < 0.05; mean ratio > 2) were included (n = 33).
Analytes with significantly different concentration in one cell line compared to all other cell lines. Metabolites of sample set 2 had to be significantly different after 24 h and after 48 h with mean ratios above 2 at both time points. Significance was assessed with Student’s t-test. p Values of the sample set 2 were calculated for each cell line against all others of the 48 h-value (n = 6; n.d. = not detected).
| Cell line | Analyte | Relative abundance | ||
|---|---|---|---|---|
| MCF-7 | Cystathione (2TMS) | Increased | n.d. | 1.2×10−6 |
| Asparagine DL (3TMS) | Increased | 0.05 | 2.6×10−4 | |
| Gulonic acid (6TMS) | Increased | 0.37 | 1.3×10−3 | |
| Piperidine-2-one, 3-amino (2TMS) | Increased | n.d. | 6.6×10−3 | |
| Proline 4-hydroxy-(3TMS) | Increased | 0.03 | 5.8×10−5 | |
| Hexadecan-1-ol, n- (1TMS) | Increased | 0.02 | 4.4×10−4 | |
| Arginine DL --NH3 (3TMS) | Increased | n.d. | 2.6×10−3 | |
| Ornithine DL (4TMS) | Increased | 0.19 | 6.6×10−5 | |
| Ornithine DL (3TMS) | Increased | n.d. | 5.0×10−3 | |
| Inositol | Decreased | 6.2×10-13 | 6.6×10−8 | |
| Alanine beta (3TMS) | Decreased | 2.6×10-5 | 1.7×10−9 | |
| Octadecan-1-ol, n- (1TMS) | Increased | 0.04 | 2.4×10−4 | |
| JIMT-1 | Pantothenic acid D (3TMS) | Increased | 0.08 | 1.2×10−5 |
| Alanine (2TMS) | Increased | 1.4×10-4 | 5.3×10−4 | |
| Glutaric acid, 2-hydroxy (3TMS) | Increased | n.d. | 2.1×10−9 | |
| Glutamine DL (4TMS) | Decreased | n.d. | 9.3×10−6 |
Figure 2(A) Lactate release for the cell lines. Signal ratios were calculated by dividing signals from medium samples with cells by the signal of medium blank measurements; (B) pH difference between medium blank and cultivation medium after 24 h and 48 h; (C) maximum normalized enzyme activities for LDH and Glo1 for the five cell lines; same letters indicate no significant difference, different letters = significant difference between cells with p < 0.05. n = 6 for lactic acid release, pH value and Glo1 activity, n = 4 for LDH activity; and (D) Correlation between LDH activity and Glo1 activity in cells.
Pearson’s correlation between extracellular lactate, Glo1 and LDH activity, number of migrated cells (migration) and relative metabolite intensities for the five breast cancer cell lines (sample set 1), and for the breast cancer cell lines and an Glo1 knockdown mutant MCF-7siGlo1 and the corresponding mock transfected control cells of the cell line MCF-7, MCF-7 mock (sample set 2). The dataset was calculated on basis of mean values, n = 6 for the metabolite profiles and Glo1 activity per cell line, n = 5 for cell migration, n = 4 for LDH activity.
| Sample set | extracellular lactate* | Glo1 activity | LDH activity | Cell migration | |||||
|---|---|---|---|---|---|---|---|---|---|
| r | p | r | p | r | p | r | p | ||
| Glycerophosphoglycerol (5TMS) | 2 | 0.77 | 0.009 | 0.87 | 0.001 | 0.91 | 9.50×10−5 | 0.98 | 5.03×10−7 |
| 1 | 0.81 | 0.085 | 0.88 | 0.016 | 0.95 | 0.002 | 0.78 | 0.057 | |
| Pantothenic acid D (3TMS) | 2 | 0.87 | 0.001 | 0.84 | 0.001 | 0.85 | 0.001 | 0.86 | 0.001 |
| 1 | 0.67 | 0.282 | 0.91 | 0.007 | 0.85 | 0.026 | 0.95 | 0.002 | |
| Alanine, beta- (3TMS) | 2 | 0.91 | 1.24×10−4 | 0.63 | 0.069 | 0.82 | 0.003 | 0.82 | 0.003 |
| 1 | 0.99 | 2.38×10−4 | 0.63 | 0.204 | 0.85 | 0.023 | 0.63 | 0.206 | |
| extracellular lactate | 2 | 0.84 | 0.002 | 0.80 | 0.004 | 0.85 | 0.001 | ||
| 1 | 0.72 | 0.104 | 0.89 | 0.013 | 0.82 | 0.037 | |||
| Glo1 activity | 2 | 0.84 | 0.002 | 0.76 | 0.010 | 0.86 | 0.001 | ||
| 1 | 0.72 | 0.197 | 0.94 | 0.004 | 0.86 | 0.020 | |||
| LDH activity | 2 | 0.80 | 0.004 | 0.76 | 0.010 | 0.92 | 9.25×10−5 | ||
| 1 | 0.89 | 0.029 | 0.94 | 0.004 | 0.81 | 0.040 | |||
| Cell migration | 2 | 0.85 | 0.001 | 0.86 | 0.001 | 0.92 | 9.25×10−5 | ||
| 1 | 0.82 | 0.078 | 0.86 | 0.020 | 0.81 | 0.040 | |||
*extracellular lactate was not analyzed for MDA-MB-435, therefore n = 4 for this correlation using values from sample set 1.